1) 次の英文を参考にした。”I will follow that system of regimen which, according to my ability and judgement, I consider for the benefit of my patients.” Oath of Hippocrates In: Harvard Classics, Volume 38. P.F. Collier and Son, Boston: 1910.
2) Takano T: From the Universality to the Humanity. The 46th Japan-America Student Conference Philosophies of Life and Human Issues Table. 1994.
（http://homepage2.nifty.com/toshimitakano/2-8/08.htmlで見ることができる）
3) Guyatt GH: Evidence-based medicine. ACP Journal Club. 1991 Mar-April; 114: A-16.
4) 広井良典「医療情報の不確実性と医療システム改革」、村上陽一郎編「21世紀の『医』はどこに向かうか」、NTT出版、2000年
5) 広井良典「『エビデンス』とは何か—科学史から見たEBM、医学界新聞第2381号、医学書院、2000年
6) Schwartz S. Richardson J. Glasziou PP: Quality-adjusted life years: origins, measurements, applications, objections. Australian Journal of Public Health. 17(3):272-8, 1993
7) Rosser R. Kind P: A scale of valuations of states of illness: is there a social consensus?, International Journal of Epidemiology. 7(4):347-58, 1978
8) La Puma J. Lawlor EF: Quality-adjusted life-years. Ethical implications for physicians and policymakers. JAMA. 263(21):2917-21, 1990
9) Weeks J: Measurement of utilities and quality-adjusted survival. Oncology. 9 (11 suppl):67-70, 1995
10) O’leary JF. Fairclough DL. Jankowski MK. Weeks JC: Comparison of time-tradeoff utilities and rating scale values in cancer patients and their relatives. J Med Dec Making 15:132-137, 1995
11) Dougherty CJ: Quality-adjusted life years and the ethical values of health care.　American Journal of Physical Medicine & Rehabilitation. 73(1):61-5, 1994
12) Ludwig Breast Cancer Study Group: Randomized trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1:1256-1260, 1984
13) Gelber RD. Goldhirsch A. for the Ludwig Breast Cancer Study Group: A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. Journal of Clinical Oncology 4:1772-1779, 1986
14) Goldhirsch A. Gelber RD. Simes RJ. Glasziou P. Coates AS: Costs and benefits of adjuvant therapy in breast cancer：a quality-adjusted survival analysis. Journal of Clinical Oncology. 7:36-44, 1989
15) Glasziou PP. Cole BF. Gelber RD. Hilden J. Simes RJ: Quality adjusted survival analysis with repeated quality of life measures. Statistics in Medicine 17(11):1215-29, 1998
16) Cole BF. Gelber RD. Goldhirsch A: A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group. Statistics in Medicine. 14(16):1771-84, 1995
17) Gelber RD. Goldhirsch A. Cole BF: Evaluation of effectiveness: Q-TWiST. Cancer Treatment Reviews 19 (supplement A), 73-84, 1993
18) International Breast Cancer Study Group: Duration and reintroduction of adjuvant breast cancer for node-positive premenopausal breast cancer patients. Journal of Clinical Oncology 14: 1885-1894, 1996
19) Sackett DL, Straus SE, Richardson WS, et al: Evidence-Based Medicine, How to Practice and Teach EBM, Second Edition. Churchill Livingston, Edinburgh, UK, 2000
20) 高野利実：エビデンスは患者と医師の共通言語、特集「Evidence Based Medicineの現在」癌診療の現場から、EBMジャーナルVol.4 No.2、2003年
21) 近藤誠「患者よ、がんと闘うな」、文藝春秋、1996年
22) 平岩正樹「医者に聞けない抗癌剤の話」、海竜社、1999年